Moderna Pays Up to $2.25 Billion to End COVID Vaccine Patent War
Moderna agrees to $2.25B settlement with Arbutus Biopharma and Genevant, paying $950M upfront + up to $1.3B contingent. Ends all COVID vaccine patent litigation worldwide.
/ 18 items
#MRNA↓
FDA Reverses Decision: Agrees to Review Moderna's New mRNA Flu Vaccine
The FDA has flipped its stance and will now review Moderna's mRNA-1010 flu vaccine for adults 50+, after an initial rejection caused controversy. Decision sets August 5, 2026, target date.
Moderna Surpasses Q4 Revenue Expectations Despite Vaccine Hurdles
Moderna reported $678M in fourth-quarter sales, beating Wall Street forecasts, while facing FDA rejection on its flu shot. The company eyes 10% growth in 2026 amid cost cuts and new deals.
FDA Rejects Review of Moderna's New mRNA Flu Vaccine: What Happened?
Vinay Prasad, FDA's biologics director, overruled staff to refuse reviewing Moderna's new mRNA flu vaccine, citing trial design issues. HHS denies overruling occurred amid ongoing debate on vaccine scrutiny.
FDA Rejects Moderna's mRNA Flu Vaccine Application
FDA refuses to review Moderna's innovative mRNA flu vaccine over clinical trial design concerns, sending shares down 7%. Company disputes decision citing prior agency approval.
Arbutus vs. Moderna Patent Case Heads to Jury Trial
Arbutus Biopharma stock rises 5% as judge orders jury trial in patent dispute over mRNA vaccine technology with Moderna, with trial set for March.